Amoxicillin News and Research

RSS

Recent surge in group A streptococcal infections among children in UK

In an editorial published in the journal New Microbes and New Infections, scientists have highlighted the possible reasons behind a sudden rise in cases of group A streptococcal infections among children in the United Kingdom and other European countries.

18 Dec 2022

The incidence of antimicrobial resistance among urinary E. coli isolates is increasing in both hospital and community settings in Australia

Researchers comparatively evaluated trends in AMR among urinary Escherichia coli strains from a private, commercial community-based laboratory and a public HB laboratory in the Illawarra Shoalhaven area located in NSW, Australia.

1 Dec 2022

Researchers discover how hydroquinine inhibits major drug-resistant bacteria

Researchers say hydroquinine could be an effective weapon against a germ that can cause serious infections in humans, mostly hospital patients

28 Oct 2022

Antibiotic exposure in early childhood linked to later development of asthma and allergies

Early exposure to antibiotics kills healthy bacteria in the digestive tract and can cause asthma and allergies, a new study demonstrates.

28 Jul 2022

Two cases of MIS-C after laboratory-confirmed SARS-CoV-2 breakthrough infections in fully vaccinated adolescent patients

Researchers investigated whether COVID-19 vaccination effectively protected adolescents in the United States from multisystem inflammatory syndrome (MIS).

2 Jun 2022

Aston University’s new antibiotic combination forms part of a lifesaving treatment for cystic fibrosis

A new antibiotic combination developed by researchers at Aston University has formed part of a lifesaving treatment used in the USA.

26 May 2022

New study reveals oral opaganib's potent in vitro activity against Omicron

RedHill Biopharma Ltd., a specialty biopharmaceutical company, today announced study results in which opaganib (ABC294640), a leading oral drug candidate for hospitalized patients with moderate to severe COVID-19, was observed to have potent in vitro efficacy against the Omicron SARS-CoV-2 variant, while maintaining host cell viability.

11 Apr 2022

Phase 2/3 study of oral RHB-107 in non-hospitalized COVID-19 patients shows promising results

RedHill Biopharma Ltd., a specialty biopharmaceutical company, today announced positive top-line results from the Phase 2 part of the Phase 2/3 study of once-daily oral RHB-107 (upamostat) in non-hospitalized symptomatic COVID-19 patients, predominantly conducted in the U.S. (60/61 patients) as well as South Africa.

1 Mar 2022

Antibiotics provide no benefit in preventing recurrent wheezing in infants hospitalized with RSV

Antibiotics provide no benefit in preventing future recurrent wheezing in babies hospitalized with respiratory syncytial virus (RSV), according to a new study led by Washington University School of Medicine in St. Louis. And there is some evidence that antibiotics may make wheezing worse.

27 Feb 2022

Rarely-used antibiotic could be a safe and affordable treatment for neonatal sepsis

An antibiotic rarely used in infants admitted to hospitals could be a safe and affordable, life-saving treatment for neonatal sepsis, in the face of growing resistance to other drugs, a study finds.

24 Feb 2022

Cessation of antibiotic prophylaxis in dentistry led to no increase in infective endocarditis

Sweden is one of the few countries that have removed the dental health recommendation to give prophylactic antibiotics to people at a higher risk of infection of the heart valves, so-called infective endocarditis.

17 Feb 2022

Study shows risk of MIS-C post mRNA vaccination against COVID-19 in children with autoimmune complications

Researchers discuss two cases of MIS-V after the patients had received the SARS-CoV-2 vaccine from Pfizer/BioNTech (BNT162b2).

23 Nov 2021

Large trial finds little effect of antibiotic amoxicillin for treating chest infections in children

The largest randomized placebo-controlled trial of the antibiotic amoxicillin for treating chest infections in children - one of the most common acute illnesses treated in primary care in developed countries, has found it is little more effective at relieving symptoms than the use of no medication.

28 Sep 2021

Early life exposure to antibiotics could alter brain development

Antibiotic exposure early in life could alter human brain development in areas responsible for cognitive and emotional functions, according to a Rutgers researcher.

14 Jul 2021

Novel technique helps evaluate the effect of potential inhibitors on antibiotic-resistant bacteria

Researchers from the Miami University in Ohio have optimized a new technique that will allow scientists to evaluate how potential inhibitors work on antibiotic-resistant bacteria.

21 Jun 2021

Redhill Biopharma announces completion of enrollment for oral opaganib phase 2/3 COVID-19 study

RedHill Biopharma Ltd., a specialty biopharmaceutical company, today announced that it has completed enrollment and randomized the last patient in the global Phase 2/3 study with opaganib (Yeliva, ABC294640) in patients hospitalized with severe COVID-19 pneumonia (NCT04467840).

7 Jun 2021

Cholestenone could be a new antibacterial drug against H. pylori

Helicobacter pylori (H. pylori), a gram-negative pathogen that has infected half of the world's population is a Group I carcinogen according to the WHO. H. pylori resides in the gastric mucosa causing gastritis, ulcers, gastric cancers and malignant lymphoma of the stomach.

27 Apr 2021

Five-day course of high-dose antibiotic will do just as well for children with pneumonia

Many parents know the struggle of having to make children with pneumonia finish the usual 10-day course in antibiotics despite the child feeling better after a few days of medication.

8 Mar 2021

Study profiles the nose to predict immune response during COVID-19

SARS-CoV-2 resides in mucous membranes, making it easy to detect viral load in the nasal cavities. An international group of researchers has characterized the immunological and diagnosis characteristics of patients who may have or are confirmed with SARS-CoV-2 infection. The team found a distinct nasal cytokine profile that could help identify patients at risk for high inflammatory responses to SARS-CoV-2 infection.

22 Feb 2021

Complication of severe SARS-CoV-2 pneumonia results in persistent cortical blindness: Case report

A study recently published in the journal Cureus has described a case report of a coronavirus disease 2019 (COVID-19) patient who presented with pneumonia, posterior reversible encephalopathy syndrome (PRES), and persistent cortical blindness. A detailed clinical presentation of the patient is provided in the report.

31 Jan 2021